Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in: Gastric Cancer 2/2002

01-06-2002 | Original article

The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas

Authors: Yasushi Takahama, Yukishige Yamada, Koji Emoto, Heisuke Fujimoto, Tomoyoshi Takayama, Masatoh Ueno, Hideki Uchida, Shuya Hirao, Takashi Mizuno, Yoshiyuki Nakajima

Published in: Gastric Cancer | Issue 2/2002

Login to get access
Metadata
Title
The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas
Authors
Yasushi Takahama
Yukishige Yamada
Koji Emoto
Heisuke Fujimoto
Tomoyoshi Takayama
Masatoh Ueno
Hideki Uchida
Shuya Hirao
Takashi Mizuno
Yoshiyuki Nakajima
Publication date
01-06-2002
Publisher
Springer-Verlag
Published in
Gastric Cancer / Issue 2/2002
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s101200200011

Other articles of this Issue 2/2002

Gastric Cancer 2/2002 Go to the issue

Case report

A patient with primary gastric choriocarcinoma who received a correct preoperative diagnosis and achieved prolonged survival

Editorial

Grading of gastritis: an impossible dream?

Case report

Rare case of early mucosal gastric cancer presenting with metastasis to the bulbar conjunctiva

Editorial

A new paradigm of chemotherapy for gastric cancer: speeding up, and more clinical trials to catch up

Original article

Quantitative detection of disseminated cancer cells in the greater omentum of gastric carcinoma patients with real-time RT-PCR: a comparison with peritoneal lavage cytology

Original article

Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits